SOURCE: Elsevier Business Intelligence

Elsevier Business Intelligence

January 25, 2010 09:00 ET

Regulatory and Medtech Business Experts Will Reveal How the FDA's 510(k) Programs Are Changing at Elsevier's 'IN3 WEST' Investor Conference, Las Vegas, March 4-5, 2010

Largest Annual Strategic Partnership and Investment Meeting Follows 'Medical Device Investor Day' at Same Venue on March 3rd

LAS VEGAS, NV--(Marketwire - January 25, 2010) - Elsevier Business Intelligence, the medtech industry's leading strategic partner and investment conference organizer, announced today that it will host 'IN3 West' on March 4-5, 2010, at The Venetian Resort-Hotel-Casino, Las Vegas. This annual event follows 'Medical Device Investor Day', also being held at The Venetian, on March 3rd, 2010.

Medical device start-ups face intense competition for a finite amount of available capital funding. IN3 events offer an unparalleled experience for emerging companies to meet and impress potential investors from many of the top-tier device companies and discerning healthcare investment firms from around the world.

"There is no doubt: Fears are afoot that 510(k) clearances are no longer as quick, easy and inexpensive as they used to be -- and that companies hoping to enter the market via 510(k) are no longer a guaranteed low-risk investment," said David Cassak, Editor and Managing Director at Elsevier Business Intelligence. "How real are these concerns? How, exactly, is the FDA's 510(k) program changing? And what are the real-life experiences of companies that have recently used the process? Our IN3 West meeting will feature regulatory and business experts who will share their up-to-date knowledge at one of our panel sessions, so attendees can decide for themselves whether investing in a 510(k) strategy is still viable."

Participants at the upcoming 'IN3 West' meeting in Las Vegas who will share their criteria about where to place device bets in 2010 will include investors and corporate development executives from RCT BioVentures, Prism Ventures, Pappas Ventures, Delphi Ventures, New Leaf Venture Partners, Stryker, Synergy Life Science Partners, Essex Woodlands Health Ventures and Domain Associates, among others.

The prelude to IN3 West will be Medical Device Investor Day on March 3rd, also at The Venetian Resort-Hotel, Las Vegas. This special event will bring together early-, mid-, and late-stage medtech innovators along with the biggest medical device dealmakers in financing, partnering, and M&A. Medical Device Investor Day is critically important to medtech innovators interested in what the investment leaders in the space are looking for in terms of technologies, therapeutic areas, products, and geographic markets. They will specifically disclose partnering opportunities and how to maximize visibility in front of big-company investors, as well as discuss what the landscape for M&A is expected to look like in this new year.

For more information about IN3 West and Medical Device Investor Day, please contact: Kristy Grimes at 1-480-985-9512 or Kayleen Kell at 1-888-290-2225 (USA only), or email IN3@Elsevier.com.

Additional IN3 events in 2010: April 29-30: IN3 Europe, Paris: "Bridging European and U.S. Medical Device Innovators, Investors and Companies" (Marriott Rive Gauche Hotel). For more information, please contact: Kristy Grimes at 1-480-985-9512 or Kayleen Kell at 1-888-290-2225 (USA only), or email IN3@Elsevier.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as Science Direct (www.sciencedirect.com), MDConsult (www.mdconsult.com), Nursing Consult (www.nursingconsult.com), Scopus (www.info.scopus.com), bibliographic databases, and online reference works.

Elsevier (www.elsevier.com) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (www.reedelsevier.com), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact Information